Targeting obesity for therapeutic intervention in heart failure patients.
Expert Rev Cardiovasc Ther
; 22(6): 217-230, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38864827
ABSTRACT
INTRODUCTION:
Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous syndrome, making it challenging to improve prognosis with pharmacotherapy. Obesity is one of the leading phenotypes of HFpEF, and its prevalence continues to grow worldwide. Consequently, obesity-targeted interventions have attracted attention as a novel treatment strategy for HFpEF. AREAS COVERED The authors review the association between the pathogenesis of obesity and HFpEF and the potential for obesity-targeted pharmacotherapeutic strategies in HFpEF, together with the latest evidence. The literature search was conducted in PubMed up to April 2024. EXPERT OPINION The STEP HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trials recently demonstrated that the glucagon-like peptide 1 analogue, semaglutide, improves various aspects of clinical outcomes in obese HFpEF patients and significantly reduces cardiovascular and heart failure events in non-diabetic obese patients, along with a substantial weight loss. Future clinical trials with other incretin mimetics with more potent weight loss and sub-analyses of the SELECT trial may further emphasize the importance of the obesity phenotype-based approach in the treatment of HFpEF.Key words
Heart failure; SELECT (semaglutide effects on cardiovascular outcomes in people with overweight or obesity); STEP HFpEF (semaglutide treatment effect in people with obesity and HFpEF); glucagon-like peptide 1 (GLP-1) analogue; heart failure with preserved ejection fraction (HFpEF); obesity; obesity paradox; phenotype-based approach
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stroke Volume
/
Weight Loss
/
Heart Failure
/
Obesity
Limits:
Animals
/
Humans
Language:
En
Journal:
Expert Rev Cardiovasc Ther
/
Expert rev. cardiovasc. ther
/
Expert review of cardiovascular therapy
Journal subject:
ANGIOLOGIA
/
CARDIOLOGIA
/
TERAPEUTICA
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: